John G Ullman & Associates Inc. Sells 11,400 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

John G Ullman & Associates Inc. trimmed its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 20.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 45,094 shares of the specialty pharmaceutical company's stock after selling 11,400 shares during the quarter. John G Ullman & Associates Inc. owned approximately 0.07% of Jazz Pharmaceuticals worth $5,024,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of JAZZ. Vanguard Group Inc. grew its holdings in shares of Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company's stock worth $776,551,000 after acquiring an additional 84,941 shares during the last quarter. Covestor Ltd grew its holdings in shares of Jazz Pharmaceuticals by 107.4% during the first quarter. Covestor Ltd now owns 618 shares of the specialty pharmaceutical company's stock valued at $74,000 after buying an additional 320 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Jazz Pharmaceuticals during the first quarter valued at $3,552,000. MQS Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the first quarter valued at $288,000. Finally, Advisors Asset Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 9.2% during the first quarter. Advisors Asset Management Inc. now owns 9,722 shares of the specialty pharmaceutical company's stock valued at $1,171,000 after buying an additional 819 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company's stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. This represents a 8.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,110 shares of company stock valued at $720,160. Insiders own 4.20% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on JAZZ. Cantor Fitzgerald reiterated an "overweight" rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Needham & Company LLC reiterated a "buy" rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday. Piper Sandler reiterated an "overweight" rating and set a $163.00 price target (down previously from $166.00) on shares of Jazz Pharmaceuticals in a report on Thursday. TD Cowen lowered their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Finally, Wells Fargo & Company lowered their price target on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating on the stock in a report on Thursday, August 1st. Three analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $175.33.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded up $5.86 during trading hours on Thursday, hitting $125.10. 970,514 shares of the company's stock were exchanged, compared to its average volume of 678,425. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market capitalization of $7.56 billion, a price-to-earnings ratio of 17.34, a PEG ratio of 0.98 and a beta of 0.57. The company's 50-day moving average price is $112.92 and its 200-day moving average price is $110.52.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.